![David J. Franklin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David J. Franklin
Corporate Officer/Principal bei Intarcia Therapeutics, Inc.
Aktive Positionen von David J. Franklin
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Intarcia Therapeutics, Inc.
![]() Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01.03.2006 | - |
Karriereverlauf von David J. Franklin
Ehemalige bekannte Positionen von David J. Franklin
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
IDENIX PHARMACEUTICALS INC | Vertrieb & Marketing | 01.03.2005 | 30.03.2006 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.1990 | 01.01.1995 |
Ausbildung von David J. Franklin
Gettysburg College | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sales & Marketing | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Private Unternehmen | 2 |
---|---|
Intarcia Therapeutics, Inc.
![]() Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
Idenix Pharmaceuticals LLC
![]() Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- David J. Franklin
- Erfahrung